Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2025-04-28 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2024年年度财务报告
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度财务报告" which translates to "2024 Annual Financial Report" of 康芝药业股份有限公司. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. It also includes an audit report with an unqualified opinion from a registered accounting firm, detailed audit procedures, and key audit matters. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is comprehensive and covers the full fiscal year 2024, consistent with an official annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-28 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "康芝药业股份有限公司2024 年年度报告摘要" which translates to "Kangzhi Pharmaceutical Co., Ltd. 2024 Annual Report Summary." It contains detailed financial data for the year 2024, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, industry analysis, and company operations. The document is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. It explicitly states it is a summary of the annual report and includes audited financial statements and management discussion. There is no indication that this is merely an announcement of the report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-28 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled "康芝药业股份有限公司2024 年年度报告全文" which translates to "Honz Pharmaceutical Co., Ltd. 2024 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, social responsibility, and financial statements. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial data, management analysis, and comprehensive disclosures. There is no indication that this is merely an announcement of a report or a certification document. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-28 Chinese
2024年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与使用情况专项报告" which translates to "2024 Annual Special Report on the Deposit and Use of Raised Funds." It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds by listed companies. The content details the actual raised funds, their deposit, management, usage, changes in investment projects, and related board and shareholder meeting approvals. It includes detailed tables on fund usage and changes in projects, indicating it is a specialized report on fundraising capital usage rather than a general financial report or earnings release. This type of document fits the category of "Capital/Financing Update" (CAP) as it provides updates on the company's fundraising and capital usage activities. The document length is substantial (over 13,000 characters) and contains detailed financial data related to fundraising, so it is not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-04-28 Chinese
关于向金融机构申请综合授信额度相关事项的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 康芝药业股份有限公司 regarding the application for a comprehensive credit facility from financial institutions, including the authorization of the chairman to handle related matters. It includes extensive financial data of subsidiaries, descriptions of the credit facility, guarantees, and board and supervisory opinions. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a call transcript, AGM materials, or voting results. The document is a formal announcement about financing activities, specifically about applying for credit lines and guarantees, which fits the definition of a Capital/Financing Update (CAP). The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2025-04-28 Chinese
康芝药业2024年度ESG报告
Environmental & Social Information Classification · 100% confidence The document is titled '2024 Environmental, Social and Governance (ESG) Report' and contains detailed information about the company's environmental policies, social responsibility, governance structure, environmental management systems, pollution control, and sustainability efforts. It covers the full year 2024 and is intended to inform stakeholders about the company's ESG practices and performance. The content aligns with the definition of an Environmental & Social Information report, which details the company's performance on ESG factors. The document is lengthy (15,000 characters) and contains substantive content rather than just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is Environmental & Social Information (SR).
2025-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.